25 related articles for article (PubMed ID: 37852872)
1. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Parameters of Contrast-Enhanced Ultrasound Predicting the Response to Combined Immune Checkpoint Inhibitor and Anti-angiogenesis Therapies for Unresectable Hepatocellular Carcinoma.
Zhang Y; Zheng R; Liu M; Zhang X; Sun Y; Shen H; Chen S; Cai H; Guo W; Xie X; Liu B; Huang G
Ultrasound Med Biol; 2024 Mar; 50(3):352-357. PubMed ID: 38072718
[TBL] [Abstract][Full Text] [Related]
3. Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study.
Zhang J; Zhang X; Mu H; Yu G; Xing W; Wang L; Zhang T
Front Oncol; 2021; 11():729764. PubMed ID: 34868921
[TBL] [Abstract][Full Text] [Related]
4. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
[TBL] [Abstract][Full Text] [Related]
5. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization.
Moschouris H; Malagari K; Papadaki MG; Kornezos I; Stamatiou K; Anagnostopoulos A; Chatzimichael K; Kelekis N
Diagn Interv Radiol; 2014; 20(2):136-42. PubMed ID: 24317334
[TBL] [Abstract][Full Text] [Related]
6. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
[TBL] [Abstract][Full Text] [Related]
7. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
8. Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy.
Zhao CK; Guan X; Pu YY; Zhou BY; Wang LF; Sun YK; Yin HH; Xia HS; Wang X; Han H; Xu HX
Ultrasound Med Biol; 2024 Jan; 50(1):142-149. PubMed ID: 37852872
[TBL] [Abstract][Full Text] [Related]
9. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Grutters J; Redekop K; Armstrong N; Lee K; Gloy V; Raatz H; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2013 Apr; 17(16):1-243. PubMed ID: 23611316
[TBL] [Abstract][Full Text] [Related]
10. CEUS: An essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma.
Jang HJ; Kim TK; Burns PN; Wilson SR
Eur J Radiol; 2015 Sep; 84(9):1623-35. PubMed ID: 26092406
[TBL] [Abstract][Full Text] [Related]
11. Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Fraquelli M; Nadarevic T; Colli A; Manzotti C; Giljaca V; Miletic D; Štimac D; Casazza G
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD013483. PubMed ID: 36053210
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
